Pre-made Sirtratumab benchmark antibody ( Whole mAb ADC, anti-SLITRK6 therapeutic antibody, Anti-DFNMYP Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-524

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-524 Category Tag

Product Details

Pre-Made Sirtratumab biosimilar, Whole mAb ADC, Anti-SLITRK6 Antibody: Anti-DFNMYP therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Sirtratumab vedotin is an antibody drug conjugate (ADC) that delivers a small molecule microtubule-disrupting agent, monomethyl auristatin E (MMAE), to tumor cells expressing SLITRK6.

Products Name (INN Index)

Pre-Made Sirtratumab biosimilar, Whole mAb ADC, Anti-SLITRK6 Antibody: Anti-DFNMYP therapeutic antibody

INN Name

Sirtratumab

Target

SLITRK6

Format

Whole mAb ADC

Derivation

NA

Species Reactivity

Human

CH1 Isotype

IgG2

VD LC

Kappa

Highest_Clin_Trial (Jan '20)

Phase-I

Est. Status

Active

100% SI Structure

None

99% SI Structure

None

95-98% SI Structure

None

Year Proposed

2017

Companies

Astellas/Agensys,Seattle Genetics

Conditions Approved

NA

Conditions Active

Bladder Cancer

Conditions Discontinued

NA

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

SLITRK6

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide